Effect of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive pulmonary disease.

AIM To determine the effectiveness of theophyllines in real clinical practice on moderate to severe exacerbations. METHODS A cohort of 36,492 chronic obstructive pulmonary disease (COPD) patients aged > or =50 years was reconstructed from the health administrative databases of the province of Quebec, Canada, between 1 January 1995 and 31 December 2002 to compare users of theophyllines with users of inhaled corticosteroids (ICS) and users of long-acting beta(2)-agonists (LABA) on their rate of moderate to severe COPD exacerbations. RESULTS Users of theophyllines were found to be less likely than users of LABA [crude rates 84 vs. 91 per 100 patient-years, adjusted rate ratio (RR) 0.89, 95% confidence interval (CI) 0.84, 0.95] and users of theophyllines plus ICS were found to be less likely than users of LABA plus ICS (crude rates 114 vs. 112 per 100 patient-years, adjusted RR 0.89, 95% CI 0.87, 0.92) to have moderate to severe COPD exacerbations. Users of theophyllines were found to be more likely than users of ICS to have a COPD exacerbation (crude rates 84 vs. 77 per 100 patient-years, adjusted RR 1.07, 95% CI 1.04, 1.10), and this association was even stronger among patients who had at least three exacerbations in the year prior to cohort entry (crude rates 273 vs. 213 per 100 patient-years, adjusted RR 1.28, 95% CI 1.19, 1.38). CONCLUSION The use of theophyllines was found to be associated with a reduction in the rate of COPD exacerbations among all COPD patients, but to be less effective than ICS among patients with frequent exacerbations.

[1]  Sean Keenan,et al.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. , 2007, Canadian respiratory journal.

[2]  J. George,et al.  Factors associated with medication nonadherence in patients with COPD: Chest 2005;128:3198–204 , 2006 .

[3]  A. Rossi,et al.  A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease. , 2005, Pulmonary pharmacology & therapeutics.

[4]  Y. Lacasse,et al.  Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2005, Respiratory medicine.

[5]  C. Lemière,et al.  A cohort study showed that health insurance databases were accurate to distinguish chronic obstructive pulmonary disease from asthma and classify disease severity. , 2005, Journal of clinical epidemiology.

[6]  M. Beauchesne,et al.  Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study , 2005, BMJ : British Medical Journal.

[7]  I. Chabot,et al.  Treatment Persistence with Leukotriene Receptor Antagonists and Inhaled Corticosteroids , 2005, The Journal of asthma : official journal of the Association for the Care of Asthma.

[8]  A. Vignola.  PDE4 inhibitors in COPD F a more selective approach to treatment , 2004 .

[9]  J. Bourbeau,et al.  Inhaled corticosteroids in COPD: determinants of use and trends in patient persistence with treatment. , 2004, Canadian respiratory journal.

[10]  P. Barnes.  Theophylline: new perspectives for an old drug. , 2003, American journal of respiratory and critical care medicine.

[11]  F. Maltais,et al.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease--2003. , 2003, Canadian respiratory journal.

[12]  G. Della Cioppa,et al.  Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. , 2002, Chest.

[13]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[14]  C. Murray,et al.  Burden of disease--implications for future research. , 2001, JAMA.

[15]  J. Connett,et al.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[16]  L. Pilote,et al.  Changes in the treatment and outcomes of acute myocardial infarction in Quebec, 1988-1995. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[17]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[18]  tefan,et al.  LONG-TERM TREATMENT WITH INHALED BUDESONIDE IN PERSONS WITH MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHO CONTINUE SMOKING , 2000 .

[19]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[20]  S. Menjoge,et al.  Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995. , 1999, Chest.

[21]  A. Laupacis,et al.  Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. , 1999, Chest.

[22]  D. Postma,et al.  Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. , 1999, The New England journal of medicine.

[23]  D. Faulds,et al.  Theophylline. A review of its potential steroid sparing effects in asthma. , 1998, Drugs.

[24]  L. Squassante,et al.  Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease , 1998 .

[25]  J. Bourbeau,et al.  Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. , 1998, Thorax.

[26]  P. Paggiaro,et al.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease , 1998, The Lancet.

[27]  L. Squassante,et al.  Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. SLMT02 Italian Study Group. , 1998, Clinical therapeutics.

[28]  Alan D. Lopez,et al.  Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study , 1997, The Lancet.

[29]  R. Tamblyn,et al.  The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. , 1995, Journal of clinical epidemiology.

[30]  M. Cazzola,et al.  Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. , 1995, Respiratory medicine.

[31]  C. A. Vaz Fragoso,et al.  Review of the clinical efficacy of theophylline in the treatment of chronic obstructive pulmonary disease. , 1993, The American review of respiratory disease.

[32]  E H Wagner,et al.  A chronic disease score from automated pharmacy data. , 1992, Journal of clinical epidemiology.

[33]  M. Aubier,et al.  A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. , 1989, The New England journal of medicine.

[34]  H. Chrystyn,et al.  Dose response relation to oral theophylline in severe chronic obstructive airways disease. , 1988, BMJ.

[35]  I. Ziment.  Theophylline and mucociliary clearance. , 1987, Chest.

[36]  A. Wanner.  Effects of methylxanthines on airway mucociliary function. , 1985, The American journal of medicine.

[37]  S B Boxerman,et al.  A quantitative measure of continuity of care. , 1977, Medical care.

[38]  B. Burrows,et al.  Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. , 1969, The New England journal of medicine.